Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of FXR0906 in severe hypertriglyceridemia or hypertriglyceridemia with ASCVD
CTR20263500Phase 2Active
- Sponsor
- Fosun Pharma
- Start
- Sep 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of FXR0906 in hypertriglyceridemia, sponsored by Fosun Pharma. Started Sep 2026; status: active.
02
Drugs
FXR0906
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on CTR20263500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263500.